

# Sarah Brand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8673005/publications.pdf>

Version: 2024-02-01

10  
papers

151  
citations

1478280

6  
h-index

1588896

8  
g-index

11  
all docs

11  
docs citations

11  
times ranked

326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. <i>BMJ Open</i> , 2015, 5, e007111-e007111.	0.8	74
2	Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups. <i>American Journal of Cardiology</i> , 2014, 114, 849-855.	0.7	17
3	Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3910-3918.	1.4	17
4	Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 791-799.	2.2	17
5	Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent $\beta^2$ -thalassemia. <i>Journal of Market Access &amp; Health Policy</i> , 2021, 9, 1922028.	0.8	9
6	Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 652-661.	2.2	9
7	AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis. <i>Clinical Economics and Outcomes Research</i> , 2015, 7, 441.	0.7	6
8	61. AbobotulinumtoxinA in the management of cervical dystonia (CD) in the United Kingdom (UK): a budget impact analysis (BIA). <i>Toxicon</i> , 2015, 93, S20.	0.8	0
9	SAT-296 COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE BASED ON SUBGROUP OF EMPA-REG OUTCOME. <i>Kidney International Reports</i> , 2019, 4, S132.	0.4	0
10	1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. <i>Diabetes</i> , 2020, 69, .	0.3	0